,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4-6 Southampton Crescent,Abbotsford,VIC,3067,Australia,61 3 8532 2700,61 3 9510 5955,https://starpharma.com,Biotechnology,Healthcare,"Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.",45,"{'maxAge': 1, 'name': 'Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA', 'age': 59, 'title': 'CEO, MD & Exec. Director', 'yearBorn': 1963, 'fiscalYear': 2023, 'totalPay': 757143, 'exercisedValue': 0, 'unexercisedValue': 0}",5,2,7,1,2,1693526400,1703980800,86400,4,0.15,0.15,0.135,0.15,0.15,0.15,0.135,0.15,575251200,0.0,0.803678,-7.0,10196877,10196877,1343442,3461058,3461058,0.14,0.145,0,0,61573964,0.13,0.715,14.632596,0.2124,0.4229,0.0,0.0,AUD,30561030,0.0,382222419,410492992,0.059699997,0.44381002,0.085,1.6470588,1688083200,1719705600,1688083200,-15638000,-0.04,-0.02,7.263,-1.987,ASX,EQUITY,SPL.AX,SPL.AX,STARPHARMA FPO,Starpharma Holdings Limited,970095600,Australia/Sydney,AEST,36000000,0.14,none,35180000,0.086,-15381000,8272000,3.0,3.256,4208000,23.76,0.01,-0.16672,-0.37588,-8151000,-9013125,-13533000,-0.166,-1.93702,0.0,-3.7483401,AUD,
1,4-6 Southampton Crescent,Abbotsford,VIC,3067,Australia,61 3 8532 2700,61 3 9510 5955,https://starpharma.com,Biotechnology,Healthcare,"Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.",45,"{'maxAge': 1, 'name': 'Mr. Justin  Cahill', 'title': 'CFO & Company Sec.', 'fiscalYear': 2023, 'totalPay': 127697, 'exercisedValue': 0, 'unexercisedValue': 0}",5,2,7,1,2,1693526400,1703980800,86400,4,0.15,0.15,0.135,0.15,0.15,0.15,0.135,0.15,575251200,0.0,0.803678,-7.0,10196877,10196877,1343442,3461058,3461058,0.14,0.145,0,0,61573964,0.13,0.715,14.632596,0.2124,0.4229,0.0,0.0,AUD,30561030,0.0,382222419,410492992,0.059699997,0.44381002,0.085,1.6470588,1688083200,1719705600,1688083200,-15638000,-0.04,-0.02,7.263,-1.987,ASX,EQUITY,SPL.AX,SPL.AX,STARPHARMA FPO,Starpharma Holdings Limited,970095600,Australia/Sydney,AEST,36000000,0.14,none,35180000,0.086,-15381000,8272000,3.0,3.256,4208000,23.76,0.01,-0.16672,-0.37588,-8151000,-9013125,-13533000,-0.166,-1.93702,0.0,-3.7483401,AUD,
